A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07546500 · readout in 651 d

Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (industry) · ZNTL — their whole pipeline →. With European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

420estimated

Sites

Countries

Australia, Belgium, Canada +9

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-17

actual

When the study began enrolling

Primary completion

2028-05-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-04-30

estimated

The whole study's end, after follow-up

First posted

2026-04-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Ovarian Cancer

Interventions

Drug: Investigator's choice of Chemotherapy
Drug: Azenosertib — also filed as ZN-c3

Primary outcome

what the primary-completion date above is the date OF

Progression free survival (PFS) per RECIST v1.1 as assessed by Investigator

measured Up to approximately 24 months from the enrollment of the last subject

Permalink · ZNTL's whole pipeline · Catalyst calendar · Every registered study · What changed